Bevacizumab in inflammatory eye disease.

ABSTRACT:

Purpose

To report the effect of intravitreal bevacizumab (Avastin; Genentech Inc, South San Francisco, California, USA) on visual acuity and macular thickness in patients with inflammatory choroidal neovascularization (CNV) or cystoid macular edema (CME).

Design

Retrospective, noncomparative, interventional case series.

Methods

Each eye received 1.25 mg of intravitreal bevacizumab at baseline. Follow-up examinations were scheduled at 1- to 2-month intervals, with additional injections at the discretion of the physician. Comprehensive evaluations, including Snellen best-corrected visual acuity (BVCA) and optical coherence tomography measurements, were performed at each visit. Main outcome measures were BCVA and central subfield thickness (CST), as measured by optical c

SUBMITTER: Lott MN 

PROVIDER: S-EPMC4115327 | biostudies-literature | 2009 Nov

REPOSITORIES: biostudies-literature